Preclinical models of acquired drug resistance to BRAFV600/MEK inhibitors are limited and do not provide consistent results presumably because of melanoma heterogeneity and different conditions applied to obtain and characterize drug-resistant cells that might affect the phenotype in different ways due to remarkable plasticity of melanoma [18,19,20,21,22,23,24,25]. Here, MAP2K7 is linked to melanoma.